These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16431124)

  • 1. Clinical trials design and treatment tailoring: general principles applied to breast cancer research.
    Therasse P; Carbonnelle S; Bogaerts J
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):98-105. PubMed ID: 16431124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational research and the changing face of breast cancer.
    Dowsett M
    Breast Cancer Res Treat; 2004; 87 Suppl 1():S1-2. PubMed ID: 15597214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial designs for predictive marker validation in cancer treatment trials.
    Sargent DJ; Conley BA; Allegra C; Collette L
    J Clin Oncol; 2005 Mar; 23(9):2020-7. PubMed ID: 15774793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-negative breast cancer.
    Stockmans G; Deraedt K; Wildiers H; Moerman P; Paridaens R
    Curr Opin Oncol; 2008 Nov; 20(6):614-20. PubMed ID: 18841042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing the future shape of breast cancer diagnosis, prognosis and treatment.
    Dowsett M
    Breast Cancer Res Treat; 2004; 87 Suppl 1():S27-9. PubMed ID: 15597218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genomics and clinical research for breast cancer].
    Bertucci F; Birnbaum D
    Med Sci (Paris); 2012 Mar; 28 Spec No 1():14-8. PubMed ID: 22494651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of prognostic profiling in breast cancer.
    Pusztai L
    Oncologist; 2008 Apr; 13(4):350-60. PubMed ID: 18448548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research issues affecting preoperative systemic therapy for operable breast cancer.
    Wolff AC; Berry D; Carey LA; Colleoni M; Dowsett M; Ellis M; Garber JE; Mankoff D; Paik S; Pusztai L; Smith ML; Zujewski J
    J Clin Oncol; 2008 Feb; 26(5):806-13. PubMed ID: 18258990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving decision-making in early breast cancer: who to treat and how?
    Llombart-Cussac A
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():15-24. PubMed ID: 19082929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy.
    Andre F; Pusztai L
    Nat Clin Pract Oncol; 2006 Nov; 3(11):621-32. PubMed ID: 17080180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise.
    Møller S; Jensen MB; Ejlertsen B; Bjerre KD; Larsen M; Hansen HB; Christiansen P; Mouridsen HT;
    Acta Oncol; 2008; 47(4):506-24. PubMed ID: 18465317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX.
    Kaklamani V
    Expert Rev Mol Diagn; 2006 Nov; 6(6):803-9. PubMed ID: 17140367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Integration of new and future biomarkers in the treatment of breast cancer].
    Würtz SØ; Henriksen KL; Lykkesfeldt A; Celis J; Brünner NA
    Ugeskr Laeger; 2007 Sep; 169(36):2999-3003. PubMed ID: 17953881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.
    Muñoz M; Estévez LG; Alvarez I; Fernández Y; Margelí M; Tusquets I; Seguí MA; Lluch A
    Cancer Treat Rev; 2008 Dec; 34(8):701-9. PubMed ID: 18922644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges for future breast cancer trials.
    Lawrence G
    Oncology (Williston Park); 1996 Nov; 10(11):1610. PubMed ID: 8953582
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.